X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs DIVIS LABORATORIES - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA DIVIS LABORATORIES FULFORD INDIA/
DIVIS LABORATORIES
 
P/E (TTM) x 398.8 38.2 1,043.2% View Chart
P/BV x 6.2 6.2 100.3% View Chart
Dividend Yield % 0.1 0.7 11.7%  

Financials

 FULFORD INDIA   DIVIS LABORATORIES
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
DIVIS LABORATORIES
Mar-18
FULFORD INDIA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs9421,142 82.5%   
Low Rs450533 84.4%   
Sales per share (Unadj.) Rs691.4146.6 471.6%  
Earnings per share (Unadj.) Rs11.533.0 34.7%  
Cash flow per share (Unadj.) Rs15.438.4 40.0%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.31.2 24.1%  
Book value per share (Unadj.) Rs380.0222.8 170.5%  
Shares outstanding (eoy) m3.90265.47 1.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.05.7 17.6%   
Avg P/E ratio x60.725.3 239.6%  
P/CF ratio (eoy) x45.321.8 207.8%  
Price / Book Value ratio x1.83.8 48.7%  
Dividend payout %17.430.3 57.6%   
Avg Mkt Cap Rs m2,714222,318 1.2%   
No. of employees `0000.410.8 4.1%   
Total wages/salary Rs m5054,561 11.1%   
Avg. sales/employee Rs Th6,073.03,616.0 167.9%   
Avg. wages/employee Rs Th1,137.4423.8 268.4%   
Avg. net profit/employee Rs Th100.7814.9 12.4%   
INCOME DATA
Net Sales Rs m2,69638,915 6.9%  
Other income Rs m1251,134 11.1%   
Total revenues Rs m2,82240,049 7.0%   
Gross profit Rs m-4612,617 -0.4%  
Depreciation Rs m151,425 1.1%   
Interest Rs m1013 71.4%   
Profit before tax Rs m5412,313 0.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m103,543 0.3%   
Profit after tax Rs m458,770 0.5%  
Gross profit margin %-1.732.4 -5.3%  
Effective tax rate %17.728.8 61.4%   
Net profit margin %1.722.5 7.4%  
BALANCE SHEET DATA
Current assets Rs m1,73845,351 3.8%   
Current liabilities Rs m5456,507 8.4%   
Net working cap to sales %44.399.8 44.3%  
Current ratio x3.27.0 45.8%  
Inventory Days Days48127 38.3%  
Debtors Days Days495 4.5%  
Net fixed assets Rs m1221,160 0.1%   
Share capital Rs m39531 7.3%   
"Free" reserves Rs m1,44358,625 2.5%   
Net worth Rs m1,48259,156 2.5%   
Long term debt Rs m00-   
Total assets Rs m2,07767,832 3.1%  
Interest coverage x6.7926.8 0.7%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.6 226.3%   
Return on assets %2.612.9 20.2%  
Return on equity %3.014.8 20.3%  
Return on capital %4.320.8 20.7%  
Exports to sales %00-   
Imports to sales %24.521.8 112.1%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m6598,485 7.8%   
Fx inflow Rs m1732,359 0.1%   
Fx outflow Rs m6739,042 7.4%   
Net fx Rs m-65623,317 -2.8%   
CASH FLOW
From Operations Rs m907,759 1.2%  
From Investments Rs m105-4,783 -2.2%  
From Financial Activity Rs m-14-3,142 0.4%  
Net Cashflow Rs m181-166 -108.7%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 11.8 32.2%  
FIIs % 0.1 19.0 0.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 17.2 123.3%  
Shareholders   4,783 31,796 15.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare FULFORD INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - VENUS REMEDIES COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS